抗中性粒细胞胞质抗体相关性血管炎糖皮质激素治疗并发症与后遗症的前瞻性研究
该单中心前瞻性研究纳入138例确诊抗中性粒细胞胞质抗体相关性血管炎(AAV)患者,用糖皮质激素毒性指数(GTI)在基线和6个月后评估毒性。中位累积糖皮质激素剂量为9014.0 mg,累积剂量≥935 mg时GTI出现临床有意义变化的可能性为80%。
要点
- 中位累积糖皮质激素剂量为9014.0 mg,最常见不良事件为皮肤萎缩、骨质疏松和肌病。
- 糖皮质激素暴露与毒性显著相关(p<0.001),活动性疾病患者GTI-AIS显著高于缓解期患者(p<0.001)。
- 累积糖皮质激素剂量≥935 mg时,GTI评分出现临床有意义变化的可能性为80%。
核心结论
- GTI能够捕捉AAV中的糖皮质激素毒性并识别糖皮质激素副作用风险增加的患者。
- 作者认为数据支持在AAV患者中限制糖皮质激素暴露。
研究设计与样本
- 单中心前瞻性研究,纳入138例确诊AAV患者。
- 通过结构化访谈、临床检查和电子病历分析评估糖皮质激素毒性。
- 在基线(t1)和6个月后(t2)两个时间点评估糖皮质激素毒性指数(GTI),包括总体改善评分(GTI-AIS)和累积恶化评分(GTI-CWS)。
- 使用回归分析评估GTI与糖皮质激素暴露、毒性和疾病活动度的关系,并用受试者工作特征分析计算毒性预期发生的糖皮质激素阈值剂量。
主要发现
- 中位累积糖皮质激素剂量为9014.0 mg。
- 最常见不良事件为皮肤萎缩、骨质疏松和肌病。
- 糖皮质激素暴露与毒性显著相关(p<0.001)。
- 活动性疾病患者GTI-AIS显著高于缓解期患者(p<0.001)。
- 长病程患者GTI-CWS评分显著更高(p=0.013),高累积糖皮质激素剂量患者GTI-CWS评分显著更高(p=0.003)。
关键数值与推荐
- 累积糖皮质激素剂量≥935 mg的患者GTI评分出现临床有意义变化的可能性为80%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glucocorticoids (GC) are a cornerstone in treating antineutrophil cytoplasmic antibodies-associated vasculitides (AAV), however, they add to morbidity and mortality. To date, GC toxicity in AAV has rarely been systematically investigated. METHODS: Patients with a confirmed AAV were included in this monocentric prospective study. GC toxicity was assessed by structured interviews, clinical examination and electronic medical record analysis. The Glucocorticoid Toxicity Index (GTI) consisting of the Aggregate Improvement Score (GTI-AIS) and the Cumulative Worsening Score (GTI-CWS) was assessed at two time points (t1 baseline, t2 6 months later). We used regression analyses to assess the relationship between GTI and GC exposure, toxicity, and disease activity, and a receiver operating characteristic analysis to calculate a GC threshold dose beyond which toxicity is expected to occur. RESULTS: We included 138 patients with AAV. The median cumulative GC dose was 9014.0 mg. The most frequent adverse events were skin atrophy, osteoporosis and myopathy. GC exposure and toxicity were significantly correlated (p<0.001). GTI-AIS was significantly higher in active disease compared with patients in remission (p<0.001). GTI-CWS scored significantly higher in long-standing diseases (p=0.013) with high cumulative GC doses (p=0.003). Patients with a cumulative GC dose of 935 mg or more showed an 80% likelihood for a clinically meaningful change in GTI scoring. CONCLUSION: The GTI is capable of capturing GC toxicity in AAV and identifies patients at increased risk for GC side effects. Our data support efforts to limit GC exposure in patients with AAV.
引用
- Scherbacher PJ, Hellmich B, Feng YS, et al. Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis. RMD Open. 2024. PMID: 38428978. doi:10.1136/rmdopen-2023-003956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。